Tips for searching:
• You have to select a product and type at least 2 words to activate the search
• Use only words that are specific to the information you are looking for
• Avoid typing questions or sentences
Please do not use this field to report adverse events or product complaints. Adverse events and product complaints should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow card in the Google play or Apple app store. Adverse events and product complaints should also be reported to Lilly: please call Lilly UK on 01256 315 000.
Abasaglar ® (basal insulin glargine)
This information is intended for UK registered healthcare professionals only in response to your search for information. For current information for all Lilly products, including Summaries of Product Characteristics, Patient Information Leaflets and Instructions for Use, please visit: www.medicines.org.uk
How long does it Take for Abasaglar® (insulin glargine) to Start Working?
The median onset of action for Abasaglar is approximately 1 to 2 hours.
Onset of Action
The onset of action for Abasalar
- varies with dose and among patient populations, and
- is expected to be shorter for patients with diabetes mellitus compared with healthy subjects.1
Additional Information in Healthy Subjects
3 single-site, randomized, double-blind, 2-treatment, 4-period, crossover, euglycemic clamp studies were conducted in healthy subjects to evaluate similarity in the pharmacokinetic and pharmacodynamic of
- Abasaglar (insulin glargine) 100 units/mL
- the United States (US) - approved version of Lantus (insulin glargine) 100 units/mL, and
- the European Union (EU) - approved version of Lantus.2
The median onset of action, defined as the time of first change of glucose infusion rate postdose, was similar between study groups and ranged from
- 0.81 to 2.10 hours for Abasaglar
- 1.70 to 1.87 hours for the US-approved version of Lantus, and
- 0.83 to 2.13 hours for the EU-approved version of Lantus.2
References
1Data on file, Eli Lilly and Company and/or one of its subsidiaries.
2Linnebjerg H, Lam ECQ, Seger ME, et al. Comparison of the pharmacokinetics and pharmacodynamics of LY2963016 insulin glargine and EU- and US-approved versions of Lantus insulin glargine in healthy subjects: three randomized euglycemic clamp studies. Diabetes Care. 2015;38(12):2226-2233. http://dx.doi.org/10.2337/dc14-2623
Date of Last Review: 13 July 2022